Patents by Inventor Uzma SAEED

Uzma SAEED has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF
    Publication number: 20260022135
    Abstract: The present invention discloses compounds useful in treatment of conditions associated with dysfunction of ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) enzyme. Specifically, the present invention discloses compound of formula (J) which exhibit inhibitory activity against ENPP1. Method of treating conditions associated with over-expression of ENPP1 gene with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.
    Type: Application
    Filed: May 1, 2025
    Publication date: January 22, 2026
    Inventors: Brahmam Pujala, Amantullah Ansari, Shreya Sapra, Pradeep S. Jadhavar, Dhananjay Pendharkar, Sreekanth A. Ramachandran, Uzma Saeed, Abhinandan Danodia, Farha Khan, Sagar Patni, Sanjeev Soni, Ashu Gupta, Sarvajit Chakravarty, Balaji Dashrath Sathe
  • Heterocyclic compounds as kinase inhibitor and uses thereof
    Patent number: 12428395
    Abstract: The present disclosure relates generally to compounds useful in treatment of conditions associated with Checkpoint kinase (CHK), particularly CHK-1 enzymes. Specifically, the present invention discloses compound of formula (IA), which exhibits inhibitory activity against CHK-1 enzymes. Methods of treating conditions associated with excessive activity of CHK-1 enzymes with such compounds is disclosed. Uses thereof, pharmaceutical compositions, kits and method of synthesis also disclosed.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: September 30, 2025
    Assignee: SPEROGENIX THERAPEUTICS LIMITED
    Inventors: Dhananjay Pendharkar, Sreekanth A. Ramachandran, Pradeep S. Jadhavar, Dayanand Panpatil, Uzma Saeed, Vivek Kumar, Dipshe Bist
  • Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof
    Patent number: 12325720
    Abstract: The present invention discloses compounds useful in treatment of conditions associated with dysfunction of ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) enzyme. Specifically, the present invention discloses compound of formula (J) which exhibit inhibitory activity against ENPP1. Method of treating conditions associated with over-expression of ENPP1 gene with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.
    Type: Grant
    Filed: June 13, 2024
    Date of Patent: June 10, 2025
    Assignee: 1cBio, Inc.
    Inventors: Brahmam Pujala, Amantullah Ansari, Shreya Sapra, Pradeep S. Jadhavar, Dhananjay Pendharkar, Sreekanth A. Ramachandran, Uzma Saeed, Abhinandan Danodia, Farha Khan, Sagar Patni, Sanjeev Soni, Ashu Gupta, Sarvajit Chakravarty, Balaji Dashrath Sathe
  • ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF
    Publication number: 20240352046
    Abstract: The present invention discloses compounds useful in treatment of conditions associated with dysfunction of ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) enzyme. Specifically, the present invention discloses compound of formula (J) which exhibit inhibitory activity against ENPP1. Method of treating conditions associated with over-expression of ENPP1 gene with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.
    Type: Application
    Filed: June 13, 2024
    Publication date: October 24, 2024
    Inventors: Brahmam Pujala, Amantullah Ansari, Shreya Sapra, Pradeep S. Jadhavar, Dhananjay Pendharkar, Sreekanth A. Ramachandran, Uzma Saeed, Abhinandan Danodia, Farha Khan, Sagar Patni, Sanjeev Soni, Ashu Gupta, Sarvajit Chakravarty, Balaji Dashrath Sathe
  • HETEROCYCLIC COMPOUNDS AS KINASE INHIBITOR AND USES THEREOF
    Publication number: 20220281842
    Abstract: The present disclosure relates generally to compounds useful in treatment of conditions associated with Checkpoint kinase (CHK), particularly CHK-1 enzymes. Specifically, the present invention discloses compound of formula (IA), which exhibits inhibitory activity against CHK-1 enzymes. Methods of treating conditions associated with excessive activity of CHK-1 enzymes with such compounds is disclosed. Uses thereof, pharmaceutical compositions, kits and method of synthesis also disclosed.
    Type: Application
    Filed: July 31, 2020
    Publication date: September 8, 2022
    Inventors: Dhananjay Pendharkar, Sreekanth A. Ramachandran, Pradeep S. Jadhavar, Dayanand Panpatil, Uzma Saeed, Vivek Kumar, Dipshe Bist
  • ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF
    Publication number: 20220135598
    Abstract: The present invention discloses compounds useful in treatment of conditions associated with dysfunction of ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) enzyme. Specifically, the present invention discloses compound of formula (J) which exhibit inhibitory activity against ENPP1. Method of treating conditions associated with over-expression of ENPP1 gene with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.
    Type: Application
    Filed: November 1, 2021
    Publication date: May 5, 2022
    Inventors: Brahmam Pujala, Amantullah Ansari, Shreya Sapra, Pradeep S. Jadhavar, Dhananjay Pendharkar, Sreekanth A. Ramachandran, Uzma Saeed, Abhinandan Danodia, Farha Khan, Sagar Patni, Sanjeev Soni, Ashu Gupta, Sarvajit Chakravarty, Balaji Dashrath Sathe
  • HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS
    Publication number: 20200206233
    Abstract: The present disclosure relates generally to compounds useful in treatment of conditions associated with mutant isocitrate dehydrogenase (mt-IDH), particularly mutant IDH1 enzymes. Specifically, the present invention discloses compound of formula (IA), which exhibits inhibitory activity against mutant IDH1 enzymes. Method of treating conditions associated with excessive activity of mutant IDH1 enzymes with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.
    Type: Application
    Filed: December 30, 2019
    Publication date: July 2, 2020
    Inventors: Sarvajit CHAKRAVARTY, Dhananjay PENDHARKAR, Sreekanth A. RAMACHANDRAN, Chandramohan BATHULA, Sanjeev SONI, Vivek KUMAR, Uzma SAEED, Abhinandan Kumar DANODIA, Ankesh SHARMA, Pradeep S. JADHAVAR